Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03740893
Title PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Institute of Cancer Research, United Kingdom
Indications

triple-receptor negative breast cancer

Therapies

Olaparib

Ceralasertib

Durvalumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.